Arie Reijerkerk

List of Publications by Year
in descending order

38	3,252	147801 31	345221 36
papers	citations	h-index	g-index

38	38	38	5290
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB Journal, 2007, 21, 3666-3676.	0.5	294
2	MicroRNAâ€155 negatively affects bloodâ€"brain barrier function during neuroinflammation. FASEB Journal, 2014, 28, 2551-2565.	0.5	220
3	Sphingosine 1â€phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia, 2010, 58, 1465-1476.	4.9	181
4	Retinoic Acid Induces Bloodâ€"Brain Barrier Development. Journal of Neuroscience, 2013, 33, 1660-1671.	3.6	171
5	Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. Journal of Controlled Release, 2012, 164, 364-369.	9.9	151
6	Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity. Journal of Immunology, 2006, 177, 2630-2637.	0.8	144
7	MicroRNAs Regulate Human Brain Endothelial Cell-Barrier Function in Inflammation: Implications for Multiple Sclerosis. Journal of Neuroscience, 2013, 33, 6857-6863.	3.6	122
8	Diapedesis of monocytes is associated with MMPâ€mediated occludin disappearance in brain endothelial cells. FASEB Journal, 2006, 20, 2550-2552.	0.5	118
9	Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the bloodâ€"brain barrier in rats. Journal of Drug Targeting, 2014, 22, 460-467.	4.4	118
10	Reduced expression of PGC-1Î± partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathologica, 2013, 125, 231-243.	7.7	114
11	Tissue-Type Plasminogen Activator Is a Multiligand Cross-Î² Structure Receptor. Current Biology, 2002, 12, 1833-1839.	3.9	102
12	Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. Journal of Neuroinflammation, 2012, 9, 133.	7.2	102
13	Fingolimod attenuates ceramide-induced bloodâ€"brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathologica, 2012, 124, 397-410.	7.7	101
14	Astrocyte-derived retinoic acid: a novel regulator of bloodâ€"brain barrier function in multiple sclerosis. Acta Neuropathologica, 2014, 128, 691-703.	7.7	100
15	Mycâ€associated zinc finger protein (MAZ) is regulated by miRâ€125b and mediates VEGFâ€induced angiogenesis in glioblastoma. FASEB Journal, 2012, 26, 2639-2647.	0.5	98
16	Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2997-E3006.	7.1	90
17	Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia, 2014, 62, 1125-1141.	4.9	88
18	Disturbed function of the bloodâ€"cerebrospinal fluid barrier aggravates neuro-inflammation. Acta Neuropathologica, 2014, 128, 267-277.	7.7	83

#	Article	IF	Citations
19	The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. Journal of Neurochemistry, 2010, 113, 447-453.	3.9	79
20	SOX-18 controls endothelial-specific claudin-5 gene expression and barrier function. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H891-H900.	3.2	77
21	Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain, 2011, 134, 555-570.	7.6	77
22	Tissue-Type Plasminogen Activator Is a Regulator of Monocyte Diapedesis through the Brain Endothelial Barrier. Journal of Immunology, 2008, 181, 3567-3574.	0.8	65
23	T lymphocytes impair P-glycoprotein function during neuroinflammation. Journal of Autoimmunity, 2010, 34, 416-425.	6.5	59
24	Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo. Drug Discovery Today: Technologies, 2016, 20, 59-69.	4.0	59
25	P-Glycoprotein Acts as an Immunomodulator during Neuroinflammation. PLoS ONE, 2009, 4, e8212.	2.5	56
26	Brain endothelial barrier passage by monocytes is controlled by the endothelin system. Journal of Neurochemistry, 2012, 121, 730-737.	3.9	53
27	Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Letters, 2003, 539, 149-155.	2.8	50
28	Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation. FASEB Journal, 2016, 30, 2662-2672.	0.5	49
29	P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma. Acta Neuropathologica, 2014, 127, 699-711.	7.7	40
30	Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2014, 274, 96-101.	2.3	40
31	Protective effects of peroxiredoxin-1 at the injured bloodâ€“brain barrier. Free Radical Biology and Medicine, 2008, 45, 256-264.	2.9	32
32	Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Molecular Cancer Research, 2003, 1, 561-8.	3.4	30
33	Do antiangiogenic protein fragments have amyloid properties?. Blood, 2004, 104, 1601-1605.	1.4	25
34	Roles for HBâ€EGF and CD9 in multiple sclerosis. Glia, 2013, 61, 1890-1905.	4.9	25
35	Systemic Treatment With Glutathione PEGylated Liposomal Methylprednisolone (2B3-201) Improves Therapeutic Efficacy in a Model of Ocular Inflammation. , 2014, 55, 2788.		23
36	The Role of the Fibrinolytic System in Corneal Angiogenesis. Angiogenesis, 2003, 6, 311-316.	7.2	15

#	Article	IF	Citations
37	Disease Influence on BBB Transport in Inflammatory Disorders. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 573-589.	0.6	1
38	Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies. , 2015, , 463-482.		0